SCHEMBL6824022

SCHEMBL6824022

CCCCC/C=C/c1cc2cc(Cl)ccc2s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
OXER1 Q8TDS5 3/20 0.36
ATP4A P20648 1/20 0.34
ATP4B P51164 1/20 0.34
CNR1 P21554 1/20 0.34
HSP90AA1 P07900 3/20 0.32
HSP90AB1 P08238 1/20 0.32
NPC1 O15118 1/20 0.32
TUBB4A P04350 2/20 0.32
TUBB P07437 2/20 0.32
TUBA3C P0DPH7 2/20 0.32
TUBA1B P68363 2/20 0.32
TUBA4A P68366 2/20 0.32
TUBB4B P68371 2/20 0.32
TUBB3 Q13509 2/20 0.32
TUBB2A Q13885 2/20 0.32
TUBB8 Q3ZCM7 2/20 0.32
TUBA3E Q6PEY2 2/20 0.32
TUBA1A Q71U36 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824024 1.00 CYP2A6 (0.38) CYP2A6L3MBTL1OXER1ATP4AATP4B
SCHEMBL25782528 0.81 TAAR1 (0.37) NPC1
SCHEMBL15688496 0.70 TDP1 (0.43) L3MBTL1NPC1MEN1POLBKMT2A
SCHEMBL15688498 0.70 TDP1 (0.43) L3MBTL1NPC1MEN1POLBKMT2A
SCHEMBL3698530 0.69 PYGL (0.41) L3MBTL1NPC1MEN1KMT2A
SCHEMBL3698532 0.69 PYGL (0.41) L3MBTL1NPC1MEN1KMT2A
SCHEMBL6959242 0.69 CYP19A1 (0.43) CYP2A6
SCHEMBL2009283 0.67 KCNH2 (0.60) L3MBTL1CNR1TNNC1KCNH2
SCHEMBL2009287 0.67 KCNH2 (0.60) L3MBTL1CNR1TNNC1KCNH2
SCHEMBL3436152 0.65 PDE5A (0.44) L3MBTL1NPC1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R CYP2A6 2270/4885L3MBTL1 3951/4885OXER1 4193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.